Ahrum Min
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahrum Min has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Kyung-Hun Lee
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
14 shared publications - Seock-Ah Im
Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
14 shared publications - Koung Jin Suh
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
12 shared publications Seongyeong Kim
11 shared publications- Yaewon Yang
Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea
11 shared publications Debora Keunyoung Kim
10 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (5) , 395
Poly(ADP-ribose) Polymerase Inhibitor Talazoparib Inhibits DNA Damage Repair in Breast Cancer Cell Lines With or Without BRCA1/2 Mutation
Lee M, et al. J Breast Cancer. 2026 ;29:e34. https://doi.org/10.4048/jbc.2026.0085
- 1 January 2026
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (5) , 395
Open AccessPoly(ADP-ribose) Polymerase Inhibitor Talazoparib Inhibits DNA Damage Repair in Breast Cancer Cell Lines With or Without BRCA1/2 Mutation
Lee M, et al. J Breast Cancer. 2026 ;29:e34. https://doi.org/10.4048/jbc.2026.0085
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Androgen receptor expression in breast cancer cell lines
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Androgen receptor expression in breast cancer cell lines
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Androgen receptor expression in breast cancer cell lines
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
Androgen receptor expression in breast cancer cell lines
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
TOPORS expression determined the combined effects of AZD3514 and olaparib
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response
TOPORS expression determined the combined effects of AZD3514 and olaparib